Imfinzi – Page 2

AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study

12 months ago talkbio0Tagged AstraZeneca, Disease-Free Survival, Imfinzi, Malignant neoplasm of lung, Malignant neoplasm of urinary bladder, Phase 3 Clinical Trials

AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival

AstraZeneca’s IMFINZI Plus Chemotherapy Approved in the US for Mismatch Repair Deficient Endometrial Cancer

12 months ago talkbio0Tagged Approved, AstraZeneca, durvalumab, Imfinzi, Malignant neoplasm of endometrium, Mismatch Repair Deficiency, Pharmacotherapy, United States Food and Drug Administration

IMFINZI, durvalumab, endometrial cancer, mismatch repair deficient, chemotherapy, AstraZeneca, FDA approval

AstraZeneca’s Imfinzi Demonstrates Survival Benefit in Limited-Stage Small Cell Lung Cancer Study

1 year ago talkbio0Tagged ADRIATIC, AstraZeneca, durvalumab, Imfinzi, Immunotherapy, Limited-stage SCLC, Overall Survival, Phase 3 Clinical Trials, Progression-Free Survival, Small cell carcinoma of lung

AstraZeneca, Imfinzi (durvalumab), Small Cell Lung Cancer (SCLC), Limited-stage SCLC, ADRIATIC Phase III study, Overall Survival (OS), Progression-Free Survival (PFS), Immunotherapy